SG11201601047SA - Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents - Google Patents

Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents

Info

Publication number
SG11201601047SA
SG11201601047SA SG11201601047SA SG11201601047SA SG11201601047SA SG 11201601047S A SG11201601047S A SG 11201601047SA SG 11201601047S A SG11201601047S A SG 11201601047SA SG 11201601047S A SG11201601047S A SG 11201601047SA SG 11201601047S A SG11201601047S A SG 11201601047SA
Authority
SG
Singapore
Prior art keywords
uncialamycin
synthesis
derivatives
methods
antitumor agents
Prior art date
Application number
SG11201601047SA
Inventor
Kyriacos C Nicolaou
Min Lu
Debashis Mandal
Sanjeev Gangwar
Naidu S Chowdari
Yam B Poudel
Original Assignee
Univ Rice William M
Bristol Myers Squibb Co
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rice William M, Bristol Myers Squibb Co, Scripps Research Inst filed Critical Univ Rice William M
Publication of SG11201601047SA publication Critical patent/SG11201601047SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
SG11201601047SA 2013-08-14 2014-08-14 Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents SG11201601047SA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361865896P 2013-08-14 2013-08-14
US201361868783P 2013-08-22 2013-08-22
US201461937003P 2014-02-07 2014-02-07
PCT/US2014/051127 WO2015023879A1 (en) 2013-08-14 2014-08-14 Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents

Publications (1)

Publication Number Publication Date
SG11201601047SA true SG11201601047SA (en) 2016-03-30

Family

ID=51453866

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201601047SA SG11201601047SA (en) 2013-08-14 2014-08-14 Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents
SG10201810067YA SG10201810067YA (en) 2013-08-14 2014-08-14 Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201810067YA SG10201810067YA (en) 2013-08-14 2014-08-14 Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents

Country Status (13)

Country Link
US (3) US9777013B2 (en)
EP (1) EP3033346B1 (en)
JP (2) JP6474404B2 (en)
KR (1) KR20160068738A (en)
CN (1) CN105899515B (en)
AU (2) AU2014306592B2 (en)
CA (1) CA2921401A1 (en)
EA (1) EA201690388A1 (en)
ES (1) ES2769876T3 (en)
IL (1) IL244084B (en)
MX (2) MX368016B (en)
SG (2) SG11201601047SA (en)
WO (1) WO2015023879A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2921401A1 (en) * 2013-08-14 2015-02-19 William Marsh Rice University Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents
CN105764491A (en) 2013-12-09 2016-07-13 度瑞公司 Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
ES2809125T3 (en) 2015-09-23 2021-03-03 Bristol Myers Squibb Co Glypican-3 binding fibronectin-based scaffold molecules
EP3394096A1 (en) 2015-12-21 2018-10-31 Bristol-Myers Squibb Company Variant antibodies for site-specific conjugation
WO2018048975A1 (en) 2016-09-09 2018-03-15 Bristol-Myers Squibb Company Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment
AU2019277094A1 (en) 2018-05-29 2021-01-21 Bristol-Myers Squibb Company Modified self-immolating moieties for use in prodrugs and conjugates and methods of using and making
RS64205B1 (en) 2018-11-30 2023-06-30 Bristol Myers Squibb Co Antibody comprising a glutamine-containing light chain c-terminal extension, conjugates thereof, and methods and uses
JP2022512481A (en) 2018-12-12 2022-02-04 ブリストル－マイヤーズ スクイブ カンパニー Modified antibodies for conjugation with transglutaminase, as well as their conjugates, methods and uses.
CN109928981B (en) * 2019-04-19 2021-06-11 长沙天赐生物医药科技有限公司 Yanpu mycin analogue, preparation method and application thereof
WO2021055306A1 (en) 2019-09-16 2021-03-25 Bristol-Myers Squibb Company Dual capture method for analysis of antibody-drug conjugates
US11027253B2 (en) 2019-09-26 2021-06-08 Chevron Phillips Chemical Company Lp Systems and methods for reducing heat exchanger fouling rate

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
CA2086679A1 (en) * 1990-07-05 1992-01-06 Hermanus A. M. Verheul Receptor directed-toxin conjugates
US5281710A (en) 1990-08-01 1994-01-25 The Scripps Research Institute Dynemicin analogs: synthesis, methods of preparation and use
JP2985435B2 (en) 1990-11-05 1999-11-29 ロンザ リミテッド Method for producing 3-aminocrotonnitrile
US5162330A (en) 1990-11-05 1992-11-10 Bristol-Myers Squibb Co. Dynemicin c antibiotic, its triacetyl derivative and pharmaceutical composition containing same
US5801029A (en) 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
WO1996003124A1 (en) * 1994-07-27 1996-02-08 California Institute Of Technology Dynemicin analogs
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5739169A (en) 1996-05-31 1998-04-14 Procept, Incorporated Aromatic compounds for inhibiting immune response
DE19742706B4 (en) 1997-09-26 2013-07-25 Pieris Proteolab Ag lipocalin muteins
US6232287B1 (en) 1998-03-13 2001-05-15 The Burnham Institute Molecules that home to various selected organs or tissues
US6528481B1 (en) 1999-02-16 2003-03-04 The Burnam Institute NG2/HM proteoglycan-binding peptides that home to angiogenic vasculature and related methods
CN1371416B (en) 1999-08-24 2012-10-10 梅达里克斯公司 Human CTLA-4 antibodies and their uses
US7452964B2 (en) 2001-09-07 2008-11-18 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
US7183388B2 (en) 2001-03-30 2007-02-27 The Regents Of The University Of California Anti-MUC-1 single chain antibodies for tumor targeting
US20060223114A1 (en) 2001-04-26 2006-10-05 Avidia Research Institute Protein scaffolds and uses thereof
US7671010B2 (en) 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US8507445B2 (en) 2001-09-07 2013-08-13 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
CA2464690A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of apolipoprotein d
EP1471938A4 (en) 2002-01-09 2008-03-05 Medarex Inc Human monoclonal antibodies against cd30
WO2003104418A2 (en) 2002-06-06 2003-12-18 Research Corporation Technologies, Inc. Reconstituted polypeptides
NZ544911A (en) 2003-07-22 2008-12-24 Schering Ag RG1 antibodies and uses thereof
WO2005051976A2 (en) 2003-11-20 2005-06-09 Ansata Therapeutics, Inc. Protein and peptide ligation processes and one-step purification processes
US7517903B2 (en) 2004-05-19 2009-04-14 Medarex, Inc. Cytotoxic compounds and conjugates
EP1824796A4 (en) 2004-11-16 2010-02-17 Avidia Res Inst Protein scaffolds and uses thereof
WO2006056464A2 (en) 2004-11-26 2006-06-01 Pieris Ag Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4)
WO2006089230A2 (en) 2005-02-18 2006-08-24 Medarex, Inc. Human monoclonal antibodies to prostate specific membrane antigen (psma)
JP5249587B2 (en) 2005-02-18 2013-07-31 メダレックス， インク． Monoclonal antibody against prostate specific membrane antigen (PSMA) lacking fucosyl residues
ES2427646T5 (en) 2005-05-09 2017-08-22 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies against programmed death 1 (PD1) and methods for the treatment of cancer through the use of anti-PD-1 antibodies alone or in combination with other immunotherapeutic agents
JP5215180B2 (en) 2005-06-20 2013-06-19 メダレックス インコーポレーティッド CD19 antibody and method of use thereof
CA2623236A1 (en) 2005-09-26 2007-04-05 Medarex, Inc. Human monoclonal antibodies to cd70
WO2007038868A2 (en) * 2005-10-03 2007-04-12 The University Of British Columbia Novel enediyne compound and uses thereof
EP1963371A2 (en) 2005-12-08 2008-09-03 Medarex Inc. Human monoclonal antibodies to o8e
RS52804B (en) 2005-12-08 2013-10-31 Medarex Inc. Human monoclonal antibodies to protein tyrosine kinase 7 (ptk7) and their use
JP5167155B2 (en) 2006-03-09 2013-03-21 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム Compositions and methods related to profiling of multiple cell lines based on peptide bonds
MX2008015132A (en) 2006-05-30 2008-12-10 Genentech Inc Antibodies and immunoconjugates and uses therefor.
EP2035554B1 (en) 2006-06-29 2013-04-24 The Board of Trustees of The Leland Stanford Junior University Cell-free synthesis of proteins containing unnatural amino acids
KR20090057072A (en) 2006-09-08 2009-06-03 암브룩스, 인코포레이티드 Site specific incorporation of non-natural amino acids by vertebrate cells
SG177168A1 (en) 2006-12-01 2012-01-30 Medarex Inc Human antibodies that bind cd22 and uses thereof
NZ578354A (en) 2006-12-14 2012-01-12 Medarex Inc Antibody-partner molecule conjugates that bind cd70 and uses thereof
UY30776A1 (en) 2006-12-21 2008-07-03 Medarex Inc CD44 ANTIBODIES
ME02345B (en) 2007-07-17 2016-08-31 Squibb & Sons Llc Monoclonal antibodies against glypican-3
EP2195017B1 (en) 2007-10-01 2014-10-22 Bristol-Myers Squibb Company Human antibodies that bind mesothelin, and uses thereof
EP2653544A1 (en) 2008-02-05 2013-10-23 Bicycle Therapeutics Limited Methods and compositions
WO2010045469A2 (en) 2008-10-15 2010-04-22 The Board Of Regents Of The University Of Texas System Muc18 targeting peptides
WO2010087994A2 (en) 2009-01-30 2010-08-05 Whitehead Institute For Biomedical Research Methods for ligation and uses thereof
TW201336851A (en) * 2012-02-13 2013-09-16 必治妥美雅史谷比公司 Enediyne compounds, conjugates thereof, and uses and methods therefor
US8798431B2 (en) 2012-06-01 2014-08-05 Telefonaktiebolaget L M Ericsson (Publ) Fine-grained optical shuffle interconnect topology migration
CA2921401A1 (en) 2013-08-14 2015-02-19 William Marsh Rice University Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents

Also Published As

Publication number Publication date
CN105899515A (en) 2016-08-24
MX2019010875A (en) 2019-12-19
MX368016B (en) 2019-09-13
AU2014306592A1 (en) 2016-03-10
US20180065976A1 (en) 2018-03-08
IL244084A0 (en) 2016-04-21
EP3033346A1 (en) 2016-06-22
JP6474404B2 (en) 2019-02-27
US20190382412A1 (en) 2019-12-19
CN105899515B (en) 2020-01-14
AU2014306592B2 (en) 2019-04-04
MX2016001975A (en) 2016-11-14
IL244084B (en) 2019-08-29
SG10201810067YA (en) 2018-12-28
US10233192B2 (en) 2019-03-19
EA201690388A1 (en) 2016-07-29
CA2921401A1 (en) 2015-02-19
US9777013B2 (en) 2017-10-03
US10889590B2 (en) 2021-01-12
KR20160068738A (en) 2016-06-15
JP2019089804A (en) 2019-06-13
US20160185791A1 (en) 2016-06-30
WO2015023879A1 (en) 2015-02-19
JP2016534105A (en) 2016-11-04
EP3033346B1 (en) 2020-01-08
ES2769876T3 (en) 2020-06-29
AU2019204034A1 (en) 2019-07-04

Similar Documents

Publication Publication Date Title
HRP20170919T1 (en) Novel pyrazol derivatives
SG11201505309TA (en) Benzylamine derivatives
SG11201601047SA (en) Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents
GB201421334D0 (en) Synthesis of aeizeolite
HRP20181710T1 (en) Use of benzimidazole-proline derivatives
HK1215574A1 (en) Diazacarbazole derivatives as tau-pet-ligands tau-pet-
ZA201602198B (en) Preparation of hydroxy-benzylbenzene derivatives
SG11201602579SA (en) Bicyclic alkyne derivatives and uses thereof
HK1220456A1 (en) 6-acetylmorphine analogs, and methods for their synthesis and use 6-
PL3055307T3 (en) Substituted berbines and their synthesis
EP2958947A4 (en) Conjugate compound and uses of same
HK1216099A1 (en) Benzylamine derivatives
PT3010896T (en) New macrocyclic amidinourea derivatives, methods of preparation and uses thereof as chitinase inhibitors
EP2870133A4 (en) Tetrahydro-isohumulone derivatives, methods of making and using
IL244411A0 (en) Procedure for the synthesis of n-benzyl-n-cyclopropyl-1h-pyrazole-4-carboxamide derivatives
EP3006451A4 (en) Arbekacin derivative and production and use of same
TH1401003816A (en) Composition, synthesis, and methods of use of phenylcycloalkylmethylamine derivatives
AU2013900781A0 (en) Nacre-like composites, methods of synthesis and methods of use
GB201310660D0 (en) Synthesis of nucleosides